Centratherum anthelminticum seeds administration improved risk factor markers in metformin treated type 2 diabetic patients
Abstract
This study was designed to assess the effect of Centratherum anthelminticum seeds administration on blood and serum risk factor markers in type 2 diabetic (T2D) patients using metformin. It was a randomized non-blinded, controlled, 3month trial. T2D patients were registered from Sindh Government Hospital New Karachi, Karachi. There were 3 groups, DT (Diabetic Test, n=20), DC (Diabetic Control, n=20) HC (Healthy Control n=20, healthy individuals of similar age were selected). DC (metformin 500mg), DT (capsule of C. anthelminticum seeds powder CAPca + metformin 500mg each) and HC (CAPca 500mg) were given daily. Fasting blood glucose, body weights were monitored weekly while blood samples were collected on first and final day of the trial for biochemistry. Administration of CAPca showed significant decrease in % glycaemia (p<0.0001) and % Hb glycosylation (p<0.05) values. Serum risk factor markers including direct bilirubin & uric acid (p<0.01), creatine kinase & alanine aminotransferase (p<0.0001) and creatinine (p<0.05) were reduced significantly. CAPca administration improved blood and serum markers in healthy volunteers too. These improved blood & serum markers in T2D patients indorsed synergistic effect of CAPca with metformin to manage secondary challenges of T2D.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 20 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.